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Introduction 
Prematurity is the main cause of neonatal morbidity and mortality. Antenatal corticosteroid 
therapy has been shown to markedly reduced complications of prematurity.  A complete course 
of antenatal corticosteroid treatment is recommended to prevent pulmonary complications of 
preterm infants.  Repeating courses of antenatal corticosteroid in mothers who are at risk of 
preterm delivery is still debatable.  
 
 
 
 
Objectives 
The primary objective of the study is to examine the association between different doses of 
antenatal intramuscular (IM) dexamethasone therapy and fetal respiratory outcomes. 
 
Methodology 
Retrospective study on case records of patients who delivered preterm and received antenatal 
IM dexamethasone therapy in HUSM from the year 2003 to 2009.  Those who received IM 
dexamethasone 12.5 mg upon admission or diagnosis, followed by another dose of IM 
dexamethasone 12.5 mg, 12 hours later (total of 25 mg per day), is defined to receive a 
complete course of IM dexamethasone.  Those who did not complete two doses of IM 
dexamethasone 12.5 mg, 12 hours apart is defined to receive incomplete course of IM 
dexamethasone.  Those who were given another doses of IM dexamethasone after 1 week or 
more of the first course, is defined to receive repeat course of IM dexamethasone.  Their 
babies’ case records were reviewed to assess the fetal respiratory outcomes.  
 
Results 
We reviewed 927 case records of mothers who delivered preterm in HUSM from the year 2003 
to 2009, and 980 case records of their newborns. There were 407 of mothers received 
incomplete, 484 received complete and 36 received repeat course of IM dexamethasone.  
Thence, 435 infants exposed to incomplete, 503 infants exposed to complete and 42 infants 
exposed to repeated courses of antenatal IM dexamethasone for analysis. There were 61 
infants delivered at 24 to 28 completed weeks, 515 infants delivered at more than 28 to 34 
completed weeks, and 404 infants delivered at more than 34 to less than 37 completed weeks. 
In the group of infants who were delivered at more than 28 to 34 completed weeks gestation, a 
complete course of antenatal IM dexamethasone is significantly associated with better 
respiratory outcomes compared to those infants who were exposed to an incomplete course of 
antenatal IM dexamethasone. However, in the group of infants who were delivered at 24 to 28 
completed weeks gestation as well as those delivered at more than 34 to less than 37 
completed weeks period of gestation, there was no significant association between complete or 
incomplete course of antenatal IM dexamethasone and the respiratory outcomes.  
 
Conclusions 
A complete course of antenatal IM dexamethasone therapy significantly reduces the respiratory 
complications in the preterm infants delivered at more than 28 to 34 completed weeks period 
of gestation compared to those who were exposed to incomplete course of antenatal IM 
dexamethasone. 
 
(Penyelia Utama: Associate Professor Dr Shah Reza Johan Nor) 
(Penyelia Bersama: Dr Mohd Ismail Ibrahim) 
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ABSTRAK 
 
Pengenalan 
 
Kelahiran pramatang adalah suatu penyebab utama kepada kematian dan kecederaan atau 
penyakit di kalangan bayi yang baru lahir. Kajian menunjukkan bahawa rawatan 
kortikosteroid seperti suntikan ubat dexamethasone terbukti dapat mengurangkan 
pelbagai komplikasi di kalangan bayi yang lahir pramatang. Melengkapkan rawatan 
kortikosteroid semasa mengandung telah disyorkan kepada ibu – ibu mengandung yang 
berisiko untuk melahirkan bayi pramatang. Walaubagaimana pun, faedah dan 
keberkesanan mengulangi rawatan kortikosteroid setelah menerima rawatan lengkap 
tersebut masih lagi dalam perbahasan di kalangan pakar – pakar perbidanan dan sakit 
puan. 
 
Objektif 
 
Tujuan kajian ini adalah untuk menganalisa kaitan antara komplikasi system pernafasan 
di kalangan bayi yang lahir pramatang dengan bilangan rawatan kortikosteroid iaitu 
dexamethasone yang diberikan kepada ibu –ibu mereka semasa mengandung. 
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Metodologi 
 
Kajian retrospektif dilakukan ke atas rekod pesakit yang telah melahirkan bayi pramatang 
dan telah menerima rawatan kortikosteroid semasa mengandungkan bayi tersebut di 
Hospital Universiti Sains Malaysia (HUSM) dari tahun 2003 hingga tahun 2009. Mereka 
yang menerima dua suntikan ubat dexamethasone 12.5 mg setiap suntikan dengan selang 
12 jam setiap suntikan (25 mg sehari), sebelum bersalin ditafsirkan sebagai menerima 
rawatan lengkap dexamethasone. Mereka yang hanya sempat menerima satu suntikan 
dexamethasone 12.5 mg sebelum bersalin ditafsirkan sebagai menerima rawatan tidak 
lengkap dexamethasone. Manakala mereka yang menerima suntikan ulangan 
dexamethasone setelah seminggu atau lebih selepas melengkapkan rawatan lengkap 
tersebut adalah ditafsirkan sebagai menerima rawatan ulangan dexamethasone. Rekod 
rawatan bayi mereka dikaji untuk melihat komplikasi system pernafasan bayi tersebut. 
 
Keputusan 
 
Kami mengkaji sebanyak 927 rekod ibu-ibu mengandung yang melahirkan bayi 
pramatang dan sebanyak 980 rekod rawatan bayi mereka di HUSM dari tahun 2003 
hingga 2009. Kami dapati sebanyak 407 orang ibu mengandung menerima rawatan tidak 
lengkap dexamethasone, sebanyak 484 orang ibu mengandung menerima rawatan 
lengkap dexamethasone, dan sebanyak 36 orang ibu mengandung menerima rawatan 
ulangan dexamethasone. Ini memberikan kami sebanyak 435 orang bayi dari mereka 
yang menerina rawatan tidak lengkap dexamethasone, 503 orang bayi dari mereka yang 
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menerima rawatan lengkap dexamethasone dan sebanyak 42 orang bayi dari mereka yang 
menerima rawatan ulangan dexamethasone untuk dianalisa. Terdapat 61 orang bayi yang 
dilahirkan pramatang pada jangkamasa kandungan 24 hingga 28 minggu lengkap, 515 
bayi yang dilahirkan pramatang pada jangkamasa lebih dari 28 minggu hingga 34 minggu 
lengkap, 404 bayi yang dilahirkan pramatang pada jangkamasa lebih dari 34 minggu 
hingga kurang dari 37 minggu lengkap.  
 
Didapati bayi yang dilahirkan pramatang, pada jangkamasa kandungan diantara lebih dari 
28 minggu hingga 34 minggu lengkap, oleh ibu –ibu yang menerima rawatan lengkap 
dexamethasone mempunyai kadar kejadian RDS yang rendah, memerlukan rawatan 
surfactant yang kurang, mempunyai purata Apgar skor yang tinggi, memiliki jangkamasa 
rawatan di NICU yang pendek serta memerlukan jangkamasa bantuan mesin pernafasan 
yang singkat  berbanding bayi yang mana ibu mereka menerima rawatan dexamethasone 
tidak lengkap. Kesemua perkaitan tersebut adalah signifikan dari segi statistic. Tetapi 
bagi bayi yang dilahirkan pramatang pada jangkamasa kandungan antara 24 minggu 
hingga 28 minggu lengkap dan juga pada jangkamasa kandungan diantara lebih dari 34 
minggu hingga kurang dari 37 minggu lengkap, perkaitan antara rawatan lengkap atau 
tidak lengkap dexamethasone dan komplikasi pernafasan seperti yang tersebut di atas 
adalah tidak signifikan dari segi statistik. 
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Kesimpulan 
 
Rawatan lengkap dexamethasone berkait rapat dengan pengurangan masalah komplikasi 
pernafasan di kalangan bayi yang dilahirkan pramatang pada jangkamasa kandungan 
diantara lebih dari 28 minggu hingga 34 minggu lengkap berbanding dengan perawatan 
dexamethasone yang tidak lengkap. 
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ABSTRACT 
 
 
Introduction 
 
Prematurity is the main cause of neonatal morbidity and mortality. Antenatal 
corticosteroid therapy has been shown to markedly reduced complications of prematurity.  
A complete course of antenatal corticosteroid treatment is recommended to prevent 
pulmonary complications of preterm infants.  Repeating courses of antenatal 
corticosteroid in mothers who are at risk of preterm delivery is still debatable.  
 
Objectives 
The primary objective of the study is to examine the association between different doses 
of antenatal intramuscular (IM) dexamethasone therapy and fetal respiratory outcomes. 
 
Methodology 
Retrospective study on case records of patients who delivered preterm and received 
antenatal IM dexamethasone therapy in HUSM from the year 2003 to 2009.  Those who 
received IM dexamethasone 12.5 mg upon admission or diagnosis, followed by another 
dose of IM dexamethasone 12.5 mg, 12 hours later (total of 25 mg per day), is defined to 
receive a complete course of IM dexamethasone.  Those who did not complete two doses 
of IM dexamethasone 12.5 mg, 12 hours apart is defined to receive incomplete course of 
IM dexamethasone.  Those who were given another doses of IM dexamethasone after 1 
week or more of the first course, is defined to receive repeat course of IM 
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dexamethasone.  Their babies’ case records were reviewed to assess the fetal respiratory 
outcomes.  
 Results 
We reviewed 927 case records of mothers who delivered preterm in HUSM from the year 
2003 to 2009, and 980 case records of their newborns. There were 407 of mothers 
received incomplete, 484 received complete and 36 received repeat course of IM 
dexamethasone.  Thence, 435 infants exposed to incomplete, 503 infants exposed to 
complete and 42 infants exposed to repeated courses of antenatal IM dexamethasone for 
analysis. There were 61 infants delivered at 24 to 28 completed weeks, 515 infants 
delivered at more than 28 to 34 completed weeks, and 404 infants delivered at more than 
34 to less than 37 completed weeks. In the group of infants who were delivered at more 
than 28 to 34 completed weeks gestation, a complete course of antenatal IM 
dexamethasone is significantly associated with better respiratory outcomes compared to 
those infants who were exposed to an incomplete course of antenatal IM dexamethasone. 
However, in the group of infants who were delivered at 24 to 28 completed weeks 
gestation as well as those delivered at more than 34 to less than 37 completed weeks 
period of gestation, there was no significant association between complete or incomplete 
course of antenatal IM dexamethasone and the respiratory outcomes.  
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Conclusions 
A complete course of antenatal IM dexamethasone therapy significantly reduces the 
respiratory complications in the preterm infants delivered at more than 28 to 34 
completed weeks period of gestation compared to those who were exposed to incomplete 
course of antenatal IM dexamethasone. 
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